Contra-indications to metformin therapy are largely disregarded

Diabetic Medicine

Volumn 16, Issue 8, 1999, Pages 692-696

  Holstein, Andreas ^a   Nahrwold, D ^a   Hinze, S ^a   E H Egberts, ^a  

^a KLINIKUM LIPPE DETMOLD   (Germany)

Author keywords

Diabetes mellitus; Lactic acidosis; Metformin

Indexed keywords

METFORMIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; DRUG CONTRAINDICATION; FEMALE; HUMAN; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; FEMALE; GERMANY; HEART DISEASES; HOSPITALIZATION; HOSPITALS, GENERAL; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; PREGNANCY; PREGNANCY IN DIABETICS; RESPIRATORY INSUFFICIENCY; RISK FACTORS;

EID: 0032724997     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00115.x     Document Type: Article

References (30)

1. DeFronzo RA, Goodman AM and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541-549.
2. Fanghanel G, Sanchez-Reyes L, Trujillo C, Sottes D, Espinosa-Campos J. Metformin'S effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care 1996; 19: 1185-1189.
3. Garber AJ, Duncan TG, Goodman AM. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103: 491-497.
4. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993; 16: 621-629.
5. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554.
6. Ausschuβ 'Pharmakotherapie des Diabetes mellitus' der Deutschen Diabetes-Gesellschaft. Zur klinischen Wirksamkeit und Zweckmäβigkeit von Acarbose und Metformin in der Therapie des Diabetes mellitus. Diab Stoffw 1995; 4: 407-421.
7. Bristol-Meyers Squibb. Prescribing Information for Glucophage. Princeton, New Jersey, November 14, 1997.
8. Bundesgesundheitsamt, Monographie zu Metformin. Bundesanzeiger, 1994.
9. Hermann LS. Clinical Pharmacology of Biguanids. In Born GVR, Cuatrecasas P, Ganten D, Herken H, Melmon KL eds. Handbook of Experimental Pharmacology, Vol 119, Berlin, Heidelberg, New York; Springer Verlag, 1996; 373-407.
10. Dunn CJ, Peters DH. Metformin. A Review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721-749.
11. Mengel K. Antidiabetika. In Schwabe U, Paffrath D. eds. Arzneiverordnungs -Report 1998. Berlin, Heidelberg, New York: Springer Verlag, 1999; 93-101.
12. Bloomgarden ZT. Conference report: renal disease, metformin and the adipocyte. Diabetes Care 1996; 19: 1038-1040.
13. The UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
14. American Diabetes Association. The pharmacological treatment of hyperglycemia in NIDDM (Consensus Statement). Diabetes Care 1996; 19, Suppl. 1: S54-S61.
15. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579.
16. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998; 338: 265-266.
17. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
18. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997; 20: 925-928.
19. Hauner H. Verbreitung des Diabetes in Deutschland. Dtsch Med Wschr 1998; 123: 777-782.
20. Chalmers J, McBain AM, Brown IRF, Campbell IW. Metformin: is its use contraindicated in the elderly? Pract Diabetes 1992; 9: 51-53.
21. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications with adult adult-onset diabetes. V. evaluation of phenformin therapy. Diabetes 1975; 24, Suppl. 1: 65-184.
22. DeFronzo RA, Goodman AM. Metformin-associated mortality in US studies. N Engl J Med 1996; 334: 1612-1613.
23. Innerfield RJ. Metformin-associated mortality in US studies. N Engl J Med 1996; 334: 1611-1612.
24. Stadel BV, Gueriguian J, Fleming GA. Metformin-associated mortality in US Studies. N Engl J Med 1996; 334: 1613.
25. Psary EM, Manolio TA, Kuller LH, Kronmal RA. Cushman M, Fried LP et al. Incidence of and risk factors fur atrial fibrillation in older adults. Circulation 1997; 96: 2455-2461.
26. Cohen RD, Woods HF. The clinical presentations and classifications of lactic acidosis. In Cohen RD, Woods HF eds. Clinical and Biochemical Aspects of Lactic Acidosis. Boston: Blackwell Scientific Publications, 1976; 40-76.
27. Gan SC, Barr J, Arieff AI, Pearl RG. Biguanide-associated lactic acidosis. Case report and review of the literature. Arch Intern Med 1992; 152: 2333-2336.
28. Arzneimittelkomission der deutschen Ärzteschaft. Arzneiverordnung in der Praxis 1997; 1: Beilage zum Dtsch Ärztebl 1997; 27.
29. Brown JB, Pedula K, Barzilay J, Herson MK, Latare P. Lactic acidosis rates in Type 2 diabetes. Diabetes Care 1998; 21: 1659-1663.
30. Stackpoole PW. Metformin and lactic acidosis. Guilt by association? Diabetes Care 1998; 21: 1587-1588.